Evidence map›Paper›PMID 34298766›Full record

ArticleCancers2021

Detection of Circulating Tumor Cells and Microbial DNA Fragments in Stage III Colorectal Cancer Patients under Three versus Six Months of Adjuvant Treatment.

Asimina Koulouridi, Ippokratis Messaritakis, Emmanouil Theodorakis, Maria Chondrozoumaki, Maria Sfakianaki, Nikolaos Gouvas, John Tsiaoussis, Dimitrios Mavroudis, Maria Tzardi, John Souglakos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Asimina KoulouridiLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
Ippokratis MessaritakisLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.ORCID 0000-0003-1877-500X
Emmanouil TheodorakisLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
Maria ChondrozoumakiLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
Maria SfakianakiLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
Nikolaos GouvasMedical School, University of Cyprus, 20537 Nicosia, Cyprus.ORCID 0000-0002-6541-4226
John TsiaoussisDepartment of Anatomy, School of Medicine, University of Crete, 70013 Heraklion, Greece.ORCID 0000-0002-9892-1048
Dimitrios MavroudisLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
Maria TzardiLaboratory of Pathology, Medical School, University of Crete, 70013 Heraklion, Greece.
John SouglakosLaboratory of Translational Oncology, Medical School, University of Crete, 70013 Heraklion, Greece.
University of Crete · GRUniversity of Cyprus · CY

Funding

GastroIntestinal Cancer Study Group NAHellenic Society of Medical Oncology NA
6 · The paper itself

Abstract

Oxaliplatin-fluoropyrimidine combination therapy is the gold standard treatment for patients with stage III colorectal cancer (CRC); however, treatment duration is now under re-evaluation. The aim of the study was the evaluation of the non-inferiority of three over six months treatment with FOLFOX or CAPOX, in stage III CRC patients. Peripheral blood samples from 121 patients were collected, at three time points during treatment and evaluated for circulating tumor cells (CTCs) and microbial DNA detection (16S rRNA,

Indexed as

adjuvant chemotherapycirculating tumor cellscolorectal cancermicrobial DNAstage IIIthree vs. six months adjuvant treatment

Identifiers

PMID34298766
PMCPMC8305584
OpenAlexW3180301914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.